Axsome Therapeutics (NASDAQ:AXSM) has been assigned a $13.00 price target by stock analysts at Cantor Fitzgerald in a research note issued on Friday. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 146.21% from the company’s previous close.
Separately, Zacks Investment Research upgraded Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. Axsome Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $16.70.
Axsome Therapeutics (NASDAQ:AXSM) opened at $5.28 on Friday. Axsome Therapeutics has a twelve month low of $3.53 and a twelve month high of $7.20. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.86 and a quick ratio of 3.86.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
What are top analysts saying about Axsome Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Axsome Therapeutics Inc and related companies.